Vaccination is a key component of public health policy with demonstrated cost-effective
benefits in protecting both human and animal populations. Vaccines can be manufactured …

Introduction Over the last 20 years (2000-2019) the partners of the Global Polio Eradication
Initiative (GPEI) invested in the development and application of mathematical models of …

Although there have been no cases of serotype 2 wild poliovirus for more than 20 years,
transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic …

Individual-based models provide modularity and structural flexibility necessary for modeling
of infectious diseases at the within-host and population levels, but are challenging to …

To prevent vaccine‐associated paralytic poliomyelitis, WHO recommended withdrawal of
Oral Polio Vaccine (Serotype‐2) and a single dose of Inactivated Poliovirus Vaccine (IPV) …

Background Mass campaigns with oral poliovirus vaccine (OPV) have brought the world
close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself …

Background Expanding outbreaks of circulating vaccine-derived type 2 poliovirus (cVDPV2)
across Africa after the global withdrawal of trivalent oral poliovirus vaccine (OPV) in 2016 …

Serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and
spread to cause emergences of vaccine-derived poliovirus (VDPV2). After its global …

Background/Objectives: Although wild poliovirus type 2 has been eradicated, the prolonged
transmission of the live-attenuated virus contained in the type-2 oral polio vaccine (OPV2) in …

Delays in achieving polio eradication have led to ongoing risks of poliovirus importations
that may cause outbreaks in polio-free countries. Because of the low, but non-zero risk of …